Compare Abeona Therapeutics Inc (ABEO) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs KraneShares CSI China Internet ETF — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while KraneShares CSI China Internet ETF trades at $26.45. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | KWEB | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $42.94 |
52-Week Low | $4.17 | $23.63 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
KWEB, the KraneShares CSI China Internet ETF, trades at $25.59, up 2.44% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF offers concentrated exposure to Chinese internet and AI companies, currently near 52-week lows, benefiting from AI-driven growth and government support. Recent news highlights China's factory rebound and substantial AI infrastructure investments.
The outlook for KWEB is mixed; attractive valuations and AI tailwinds present opportunities, but risks include US-China tensions and China's economic volatility. Analyst sentiment is cautious due to geopolitical and regulatory uncertainties, though long-term growth potential in Chinese tech remains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
